The American Journal of Medicine
Volume 120, Issue 7 , Pages 623-630.e1 , July 2007

Lifetime Risk for Developing Dyslipidemia: The Framingham Offspring Study

  • Mark R. Cobain, PhD

      Affiliations

    • Department of Mathematics/Statistics and Biostatistics, Boston University, Boston, Mass
    • Corporate Research, Unilever Research, Colworth House, Bedfordshire, United Kingdom
    • ,
  • Michael J. Pencina, PhD

      Affiliations

    • Department of Mathematics/Statistics and Biostatistics, Boston University, Boston, Mass
    • National, Heart, Lung & Blood Institute’s Framingham Heart Study, Framingham, Mass
    • ,
  • Ralph B. D’Agostino Sr., PhD

      Affiliations

    • Department of Mathematics/Statistics and Biostatistics, Boston University, Boston, Mass
    • National, Heart, Lung & Blood Institute’s Framingham Heart Study, Framingham, Mass
    • ,
  • Ramachandran S. Vasan, MD

      Affiliations

    • National, Heart, Lung & Blood Institute’s Framingham Heart Study, Framingham, Mass
    • Cardiology Section, Preventive Medicine and Epidemiology, Department of Medicine, Boston University School of Medicine, Boston, Mass.
    • Corresponding Author InformationRequests for reprints should be addressed to Ramachandran S. Vasan, MD, Framingham Heart Study, 73 Mount Wayte Avenue, Suite 2, Framingham, MA 01702-5803.

References 

  1. Wilson PW. High-density lipoprotein, low-density lipoprotein and coronary artery disease. Am J Cardiol. 1990;66:7A–10A
  2. Downs JR, Clearfield M, Weis S, et al. Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–1622
  3. Shepherd J, Cobbe SM, Ford I, et al. Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia. N Engl J Med. 1995;333:1301–1308
  4. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–1158
  5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  6. Nicholls SJ, Rye KA, Barter PJ. High-density lipoproteins as therapeutic targets. Curr Opin Lipidol. 2005;16:345–349
  7. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  8. Thom T, Haase N, Rosamond W, et al. Heart Disease and Stroke Statistics--2006 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85–e151
  9. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. 35. Dallas, Texas: American Heart Association; 2005;
  10. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353:89–92
  11. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age. Circulation. 2006;113:791–798
  12. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287:1003–1010
  13. Vasan RS, Pencina MJ, Cobain M, et al. Estimated Risks for Developing Obesity in the Framingham Heart Study. Ann Intern Med. 2005;143:473–480
  14. Dawber TR, Meadors GF, Moore FE. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health. 1951;41:279–281
  15. Kannel WB, Feinleib M, McNamara PM, et al. An investigation of coronary heart disease in families (The Framingham offspring study). Am J Epidemiol. 1979;110:281–290
  16. Abel LL, Levy BB, Brodie BB, Kendall FE. A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem. 1952;195:357–366
  17. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta. 1987;166:1–8
  18. Lipid Research Clinics Program (Manual of Laboratory Operation). Bethesda, MD: National Institutes of Health; 1974;75-628
  19. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 1982;28:1379–1388
  20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  21. Demacker PN, Schade RW, Jansen RT, Van ’t LA. Intra-individual variation of serum cholesterol, triglycerides and high density lipoprotein cholesterol in normal humans. Atherosclerosis. 1982;45:259–266
  22. Beiser A, D’Agostino RB, Seshadri S, et al. Computing estimates of incidence, including lifetime risk: Alzheimer’s disease in the Framingham Study (The Practical Incidence Estimators (PIE) macro). Stat Med. 2000;19:1495–1522
  23. Pencina MJ, D’Agostino RB, Beiser A, et al. Estimating lifetime risk of developing high serum total cholesterol: Adjustment for baseline prevalence and single occasion measurements. Am J Epidemiol. 2007;165:464–472
  24. Kelley GA, Kelley KS, Tran ZV. Exercise, lipids, and lipoproteins in older adults: a meta-analysis. Prev Cardiol. 2005;8:206–214
  25. Millen BE, Franz MM, Quatromoni PA, et al. Diet and plasma lipids in women (I. Macronutrients and plasma total and low-density lipoprotein cholesterol in women: the Framingham nutrition studies). J Clin Epidemiol. 1996;49:657–663
  26. Poobalan A, Aucott L, Smith WC, et al. Effects of weight loss in overweight/obese individuals and long-term lipid outcomes--a systematic review. Obes Rev. 2004;5:43–50
  27. Wilson PW, Myers RH, Larson MG, et al. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease (The Framingham Offspring Study). JAMA. 1994;272:1666–1671
  28. Lopez-Miranda J, Ordovas JM, Mata P, et al. Effect of apolipoprotein E phenotype on diet-induced lowering of plasma low density lipoprotein cholesterol. J Lipid Res. 1994;35:1965–1975
  29. U.S. Department of Health and Human Services. Healthy People 2010. 2nd ed.. Washington, DC: U.S. Government Printing Office; 2000;
  30. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in Serum Lipids and Lipoproteins of Adults, 1960-2002. JAMA. 2005;294:1773–1781
  31. Schaefer EJ, Lamon-Fava S, Cohn SD, et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res. 1994;35:779–792
  32. Strychar IM, Champagne F, Ghadirian P, et al. Impact of receiving blood cholesterol test results on dietary change. Am J Prev Med. 1998;14:103–110
  33. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347–1360
  34. Gaynor JJ, Fever EJ, Tan C, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993;88:400–409

PII: S0002-9343(07)00044-7

doi: 10.1016/j.amjmed.2006.12.015

The American Journal of Medicine
Volume 120, Issue 7 , Pages 623-630.e1 , July 2007

Article Tools